Bexorg Received $28.3 Million Grant for Brain Research
The New Haven-based company will work to extend the BrainEx perfusion duration over a three-year project.
Updated on Oct. 7, 2026 in Alzheimer’s
Live Poll
Do you trust using AI and postmortem human brain tissue to develop new medical treatments?
New Haven-based neurology company Bexorg has secured a $28.3 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding will support a three-phase, 36-month initiative to extend the BrainEx perfusion duration from 24 hours to two weeks.
Why it matters
Current 24-hour perfusion windows limit the ability of researchers to study long-term disease processes. Extending this timeframe will allow scientists to better observe therapeutic effects and physiological changes that unfold over multiple days.
The project aims to extend BrainEx perfusion duration from the current 24-hour limit to two weeks of sustained brain physiology. The grant provides $28.3 million to support this development over a 36-month research timeline.
The players
Bexorg
Bexorg is a precision neurology company based in New Haven that uses AI-integrated brain platforms for drug discovery.
Advanced Research Projects Agency for Health
ARPA-H is a federal research agency that funds high-impact medical projects to accelerate breakthroughs in health outcomes.
Zvonimir Vrselja
Zvonimir Vrselja is a co-founder of the precision neurology company Bexorg.
Nenad Sestan
Nenad Sestan is a co-founder of Bexorg and a prominent researcher in the field of neurology.
The details
Bexorg, a precision neurology firm, utilizes AI integrated with an intact whole human brain platform to assist in drug discovery. By achieving a two-week window, the company expects to strengthen human pharmacological evidence, improve clinical trial designs, and reduce attrition rates in CNS drug development.
Timeline
October 7, 2026: Bexorg announced the receipt of the ARPA-H funding.
36 months: The total duration of the funded research project.
The Big Picture
This project aligns with the mandate of the Advanced Research Projects Agency for Health to accelerate high-impact biomedical innovation. The research represents a shift toward more robust, long-term human physiological modeling that could modernize how drugs for neurological conditions are vetted.
This technology may eventually lead to more effective treatments for neurological diseases by enabling better drug development testing. While the research is currently in the discovery phase, successful results could decrease the time and cost required to bring new medications to patients.
The takeaway
Advancing neurological research through extended brain perfusion could fundamentally improve how scientists understand disease progression. This development highlights the importance of sustained physiological models in overcoming the historically high failure rates of CNS drug development.
Further reading
Learn more about the latest developments in neurodegenerative research on our Alzheimer’s page.
More information
For more information on the research initiatives, visit the Bexorg official company website.
Live Poll
Do you trust using AI and postmortem human brain tissue to develop new medical treatments?
